Cell Proliferation News and Research

RSS

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis, Inc. today reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. Dr. Patrick Wen from the Dana Farber Cancer Institute in Boston, MA will present the data in an Oral Session (Abstract #2006) on Saturday, June 5 at 5:00 p.m. at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Exelixis, Inc. today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the online-first publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

20 May 2010

Researchers identify protein involved in pushing bladder tumors to become invasive

Bladder cancer often becomes aggressive and spreads in patients despite treatment, but now researchers at the Kimmel Cancer Center at Jefferson have identified a protein they believe is involved in pushing tumors to become invasive - and deadly.

15 May 2010

MicroStockProfit.com features investment report on ARIAD Pharmaceuticals

MicroStockProfit.com announces an investment report featuring ARIAD Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

10 May 2010

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

SNM's Molecular Imaging Center of Excellence wrapped up its Molecular Neuroimaging Symposium today in Bethesda, Md., at the Natcher Auditorium of the National Institutes of Health (NIH).

10 May 2010

Researchers investigate aberrant expression of nuclear matrix proteins in gastric cancer cells

Gastric cancer is the most common malignant gastrointestinal cancer and accounts for 25% of cancer deaths. Nuclear matrix, a filamentous protein framework for eukaryotic cellular chromatin, closely relates to DNA duplication and transcription. Research on nuclear matrix proteins will provide insight into how tumors developed.

7 May 2010

Protein PEA-15 stops T-cell proliferation

New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and autoimmune diseases, as well as the orchestration of the immune response to infection. Findings of the study are reported in a recent online issue of The FASEB Journal, a publication of The Federation of American Societies for Experimental Biology.

5 May 2010

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.

5 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin compound, which targets the c-Met receptor, demonstrating a dose-dependant reduction of tumor growth in a xenograft mouse model.

30 Apr 2010

Mothers with preeclampsia at reduced risk of developing breast cancer

Preeclampsia is a high blood pressure syndrome in pregnant mothers that is caused when the blood supply in the placenta of the developing baby is restricted. The blood-deprived placenta releases factors that cause the raise in blood pressure in the mother. Doctors have to monitor these women closely and they may be forced to deliver the baby early to protect the mother and the baby. Most women's blood pressure returns to normal levels after they deliver the placenta.

26 Apr 2010

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

Scientists from the University of Granada, Spain, have generated artificial human skin by tissular engineering basing on agarose-fibrin biomaterial. The artificial skin was grafted onto mice, and optimal development, maturation and functionality results were obtained.

23 Apr 2010

New on-off switches: SUMO protein silences developmental genes, SNP2 snips SUMO to allow gene expression

Deleting a gene in mouse embryos caused cardiac defects and early death, leading researchers to identify a mechanism that turns developmental genes off and on as an embryo matures, a team led by a scientist at The University of Texas M. D. Anderson Cancer Center reported today in Molecular Cell.

23 Apr 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron Corporation today announced five presentations by Geron scientists and collaborators on the company's telomerase inhibitor, imetelstat sodium, including the drug's activity against cancer stem cells, at the 101st American Association for Cancer Research annual meeting held in Washington D.C.

23 Apr 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

22 Apr 2010

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that data provided in a presentation entitled, "Antitumor activity of single small molecule agent targeting PI3K/mTor and HDAC," were presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010, which is being held in Washington, DC April 17-21.

21 Apr 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

21 Apr 2010

Findings may illuminate how cancer forms and migrates

Rho proteins have been described as "molecular switches" and play a role in cell migration, cell proliferation, cell death, gene expression, and multiple other common cellular functions.

21 Apr 2010

High BMI can raise risk of postmenopausal breast cancer

Reported mid-life increase in body mass index (BMI) may lead to substantially higher risk of postmenopausal breast cancer, according to results of a prospective cohort study presented at the American Association for Cancer Research 101st Annual Meeting 2010, held here April 17-21.

21 Apr 2010

Cell Proliferation News and Research

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Long-term data demonstrates clinical benefits of Exelixis XL184 for medullary thyroid cancer

Study demonstrates anti-prostate cancer properties of Modified Citrus Pectin

Researchers identify protein involved in pushing bladder tumors to become invasive

MicroStockProfit.com features investment report on ARIAD Pharmaceuticals

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

Researchers investigate aberrant expression of nuclear matrix proteins in gastric cancer cells

Protein PEA-15 stops T-cell proliferation

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Pieris AG announces preclinical data for proprietary PRS-110 Anticalin compound

Mothers with preeclampsia at reduced risk of developing breast cancer

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

New on-off switches: SUMO protein silences developmental genes, SNP2 snips SUMO to allow gene expression

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Curis presents data on CU-906 compound designed to inhibit HDAC and PI3K/mTOR targets simultaneously

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Findings may illuminate how cancer forms and migrates

High BMI can raise risk of postmenopausal breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News